3.53
price up icon0.00%   0.00
after-market 시간 외 거래: 3.42 -0.11 -3.12%
loading
전일 마감가:
$3.53
열려 있는:
$3.52
하루 거래량:
215.87K
Relative Volume:
0.52
시가총액:
$35.67M
수익:
-
순이익/손실:
$-23.87M
주가수익비율:
-0.1795
EPS:
-19.67
순현금흐름:
$-47.63M
1주 성능:
-1.40%
1개월 성능:
+26.07%
6개월 성능:
+16.12%
1년 성능:
-16.75%
1일 변동 폭
Value
$3.42
$3.58
1주일 범위
Value
$3.42
$3.74
52주 변동 폭
Value
$2.30
$4.42

폴리피드 Stock (PYPD) Company Profile

Name
명칭
Polypid Ltd
Name
전화
-
Name
주소
-
Name
직원
61
Name
트위터
Name
다음 수익 날짜
2024-11-13
Name
최신 SEC 제출 서류
Name
PYPD's Discussions on Twitter

PYPD을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
PYPD
Polypid Ltd
3.53 35.67M 0 -23.87M -47.63M -19.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

폴리피드 Stock (PYPD) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-05 개시 Roth Capital Buy
2025-06-02 재개 H.C. Wainwright Buy
2025-01-28 개시 Rodman & Renshaw Buy
2021-09-14 개시 JMP Securities Mkt Outperform
2021-07-30 개시 Cantor Fitzgerald Overweight
2020-11-24 업그레이드 Raymond James Outperform → Strong Buy
2020-08-10 개시 Alliance Global Partners Buy
2020-07-21 개시 BMO Capital Markets Outperform
2020-07-21 개시 Barclays Overweight
2020-07-21 개시 Raymond James Outperform
모두보기

폴리피드 주식(PYPD)의 최신 뉴스

pulisher
Jun 18, 2025

Roth Capital Adjusts Price Target on PolyPid to $9 From $12, Maintains Buy Rating - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Roth Capital Adjusts PolyPid (PYPD) Price Target Amid New Financing | PYPD Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

PolyPid (NASDAQ:PYPD) Given New $14.00 Price Target at JMP Securities - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

PYPD: JMP Securities Lowers Price Target While Maintaining Marke - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

PolyPid (PYPD) Price Target Adjusted Amid Financing Developments - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

PolyPid stock price target lowered to $14 at JMP on warrant dilution By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

PolyPid stock price target lowered to $14 at JMP on warrant dilution - Investing.com Australia

Jun 17, 2025
pulisher
Jun 17, 2025

PolyPid Secures $26.7 Million Post-Successful Phase 3 Trial - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Citizens JMP Adjusts Price Target for PolyPid (PYPD) Amid Warrant Developments | PYPD Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 13, 2025

FY2026 Earnings Forecast for PolyPid Issued By HC Wainwright - Defense World

Jun 13, 2025
pulisher
Jun 11, 2025

PESG Research Update: PolyPid SHIELD’s II Delivers - GlobeNewswire

Jun 11, 2025
pulisher
Jun 11, 2025

PESG Research Update: PolyPid SHIELD’s II Delivers Transformative Phase 3 Topline ResultsParadigm Shift in Surgical Infection Prevention - Yahoo

Jun 11, 2025
pulisher
Jun 11, 2025

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed - insights.citeline.com

Jun 11, 2025
pulisher
Jun 10, 2025

HC Wainwright Issues Positive Forecast for PolyPid (NASDAQ:PYPD) Stock Price - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

PolyPid reports positive phase 3 surgical infection drug trial - גלובס

Jun 10, 2025
pulisher
Jun 09, 2025

PolyPid (PYPD) Target Price Increased as Phase 3 Trial Data Impr - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid shares surge on successful D-PLEX100 trial results By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid shares surge on successful D-PLEX100 trial results - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : PolyPid Ltd.Special Call - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript - The Manila Times

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid (PYPD) Reports Positive Phase 3 Trial Results for D-PLEX100 | PYPD Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid’s D-PLEX100 Achieves Positive Phase 3 Results in SHIELD II Trial - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints - GlobeNewswire

Jun 09, 2025
pulisher
Jun 09, 2025

What is Roth Capital’s Forecast for PolyPid Q2 Earnings? - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Roth Capital Begins Coverage on PolyPid (NASDAQ:PYPD) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025 - The Manila Times

Jun 06, 2025
pulisher
Jun 06, 2025

PolyPid Ltd. to Host Conference Call on June 9 to Report Topline Data from SHIELD II Phase 3 Trial for D-PLEX100 - Nasdaq

Jun 06, 2025
pulisher
Jun 06, 2025

PolyPid to Host Conference Call and Webcast to Discuss - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

Major Clinical Trial Results: PolyPid's D-PLEX100 Shows New Data for Preventing Post-Surgery Infections - Stock Titan

Jun 06, 2025
pulisher
Jun 05, 2025

Roth Capital Initiates Coverage of PolyPid (PYPD) with Buy Recommendation - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

Roth Capital Initiates Coverage on PolyPid (PYPD) with a Buy Rat - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Roth Capital Initiates Coverage on PolyPid (PYPD) with a Buy Rating | PYPD Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Roth Capital Initiates PolyPid at Buy With $9 Price Target - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

PolyPid initiated with a Buy at Roth Capital - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

What is HC Wainwright’s Forecast for PolyPid Q2 Earnings? - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

FY2027 Earnings Estimate for PolyPid Issued By HC Wainwright - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

PolyPid (NASDAQ:PYPD) Upgraded by HC Wainwright to “Buy” Rating - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

PolyPid (NASDAQ:PYPD) Now Covered by HC Wainwright - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Wall Street Analyst Says PolyPid is a Buy with 300% Potential Upside as it nears Phase 3 Data Readout - newsblaze.com

Jun 02, 2025
pulisher
Jun 02, 2025

PYPD: Assessing & Advancing Lead Candidate D-PLEX₁₀₀, Through Clinical Trials to Improve Surgical Outcomes, Enhance Treatment Efficacy, Minimize Side Effects - Yahoo Finance

Jun 02, 2025
pulisher
Jun 02, 2025

H.C. Wainwright assumes coverage on PolyPid stock with buy rating - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

PolyPid assumed with a Buy at H.C. Wainwright - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

H.C. Wainwright assumes coverage on PolyPid stock with buy rating By Investing.com - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

PolyPid (PYPD) Receives a 'Buy' Rating from HC Wainwright & Co. - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

H.C. Wainwright Initiates Buy Coverage on PolyPid (PYPD) with $1 - GuruFocus

Jun 02, 2025
pulisher
May 31, 2025

PolyPid Ltd. (NASDAQ:PYPD) Sees Significant Growth in Short Interest - Defense World

May 31, 2025
pulisher
May 30, 2025

PolyPid Expands Share Option Plan to Boost Stakeholder Engagement - TipRanks

May 30, 2025

폴리피드 (PYPD) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
자본화:     |  볼륨(24시간):